Pacer Advisors Inc. Buys New Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Pacer Advisors Inc. purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 15,460 shares of the company’s stock, valued at approximately $374,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. KBC Group NV boosted its stake in shares of Hims & Hers Health by 107.9% during the 4th quarter. KBC Group NV now owns 8,471 shares of the company’s stock worth $205,000 after buying an additional 4,396 shares during the last quarter. Raleigh Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the period. SG Americas Securities LLC grew its position in shares of Hims & Hers Health by 44.0% in the fourth quarter. SG Americas Securities LLC now owns 104,422 shares of the company’s stock valued at $2,525,000 after purchasing an additional 31,915 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Hims & Hers Health by 115.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock worth $110,000 after buying an additional 2,442 shares during the period. Finally, Stonekeep Investments LLC boosted its position in shares of Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after acquiring an additional 882 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Citigroup lowered shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their price target for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Finally, Needham & Company LLC raised their price target on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $25.13.

Insider Buying and Selling

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the completion of the sale, the insider now directly owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 4,153 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $35.30, for a total value of $146,600.90. Following the completion of the sale, the insider now directly owns 161,497 shares of the company’s stock, valued at approximately $5,700,844.10. This trade represents a 2.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,156,332 shares of company stock valued at $33,853,055. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Up 7.7 %

NYSE:HIMS opened at $41.94 on Wednesday. The firm has a market capitalization of $9.16 billion, a P/E ratio of 95.32 and a beta of 1.35. Hims & Hers Health, Inc. has a twelve month low of $8.51 and a twelve month high of $41.98. The company has a fifty day moving average of $29.58 and a 200-day moving average of $22.86.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the prior year, the firm earned ($0.04) EPS. The business’s revenue was up 77.1% on a year-over-year basis. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.